Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Please see https://docs.google.com/spreadsheets/d/1GrnVsPCockqqdfxC9LWd6ndbzS2wpJVvTbCOAhn4DLM/edit?usp=sharing or Appendix A () for full code and algorithm definitions.Medicare timeframe: 2008 to 2018 (end of data availability)Inclusion Criteria:1. Aged >/= 65 years on the index date2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date3. At least two claims with breast cancer diagnosis measured 365 days prior to drug initiationExclusion Criteria:1. Prior history of dementia measured anytime prior to cohort entry date2. Prior history of nursing home admission anytime prior to cohort entry date3. Prior history of Anastrozole or Exemestane/Letrozole use anytime prior to cohort entry date